Clinical trials: Advanced Solid Tumors Patients
Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors
Study Purpose and Design:A Multicenter, Open-label, Exploratory Phase II Clinical Study to Evaluate the Safety and Tolerability and Preliminary Efficacy of TJ107 in Combination with Pembrolizumab Injection in Patients with…
- Trial name
- NCT05145907
- Testing
- TJ107 +Pembrolizumab
- Where
- 20 sites in China
- Volunteers
- 133 people
- Sponsor
- TJ Biopharma Co., Ltd.
Specific Advanced Solid Tumors
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Phase I multicenter, open-label, clinical and pharmacokinetic study of PM01183 in combination with gemcitabine in non-heavily pretreated patients with selected advanced solid tumors to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT01970553
- Testing
- lurbinectedin (PM01183), Gemcitabine
- Where
- 3 sites in Spain, United Kingdom
- Volunteers
- 47 people
- Sponsor
- PharmaMar
Solid Tumor
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer (i.e., solid tumors) for which standard therapy offers no curative potential.
- Trial name
- NCT03364400
- Testing
- VT1021
- Where
- 12 sites in United States
- Volunteers
- 116 people
- Sponsor
- Vigeo Therapeutics, Inc.
Solid Tumors
A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important role in protecting the body. p53 functions by activating proteins that repair DNA and kill cells that have genetic mutations such as in…
- Trial name
- NCT01664000
- Testing
- thioureidobutyronitrile
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Cellceutix Corporation
Ovarian Cancer, Solid Tumors
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
The main aim of this study are to check for side effects from TAK-853, check how much TAK-853 participants can receive without getting side effects from it, check how well TAK-853 controls symptoms, and to check how much TAK-853…
- Trial name
- NCT06390995
- Testing
- TAK-853
- Where
- 20 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Takeda
Advanced Solid Tumor, HR+/HER2- Breast Cancer
Study of AVZO-021 in Patients With Advanced Solid Tumors
This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, CCNE1 Amplification
- Trial name
- NCT05867251
- Testing
- AVZO-021, Palbociclib, Fulvestrant
- Where
- 13 sites in United States, Australia
- Volunteers
- 430 people
- Sponsor
- Avenzo Therapeutics, Inc.
Neoplasms
Monotherapy Dose Finding With BI 847325 in Solid Tumours
The aim of the Phase Ia (dose escalation) part of this trial is to assess the maximum tolerated dose (MTD) of BI 847325 administered at escalating doses in 2 treatment arms.
- Trial name
- NCT01324830
- Testing
- day 1 to day 5, day 1 to day 14
- Where
- 2 sites in Belgium
- Volunteers
- 69 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small Cell, Neoplasm Metastasis
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
This study will explore the combination of the oral drug PF-00299804 and intravenous CP-751,871 in patients with advanced solid tumor.
- Trial name
- NCT00728390
- Testing
- PF-00299804
- Where
- 5 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Pfizer
Solid Tumor, Adult
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4.
- Trial name
- NCT06265727
- Testing
- CRB-701, Anti-PD-1
- Where
- 41 sites in United States, France and 5 more
- Volunteers
- 348 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Advanced Solid Tumor, Metastatic Breast Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in…
- Trial name
- NCT03950570
- Testing
- Abraxane, ORIN1001
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- Orinove, Inc.
Locally Advanced, Recurrent or Metastatic Malignancies
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
This study was an open-label phase Ⅱ study to evaluate the safety and efficacy of SSGJ-705 Monotherapy and Combination Therapy in patients with advanced HER2-Expressing Solid Tumors.
- Trial name
- NCT07022002
- Testing
- SSGJ-705, PD-1/L1 inhibitor combined with chemotherapy, SSGJ-705 combined with chemotherapy
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Neoplasm
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461.
- Trial name
- NCT00496353
- Testing
- MK2461
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Relapsed or Refractory Lymphomas, Advanced Solid Tumor
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of escalating doses of LP-284 and to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) in patients with relapsed or…
- Trial name
- NCT06132503
- Testing
- LP-284
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Lantern Pharma Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients…
- Trial name
- NCT05268666
- Testing
- JBI-802
- Where
- 4 sites in United States
- Volunteers
- 126 people
- Sponsor
- Jubilant Therapeutics Inc.
Advanced Solid Tumours
Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours
This is a phase Ib, open-label, multicentre study of AZD1775 administered orally in monotherapy and in combination with carboplatin and paclitaxel to Asian patients with advanced solid tumours.
- Trial name
- NCT02341456
- Testing
- AZD1775, Paclitaxel, carboplatin
- Where
- 7 sites in Australia, Japan and 1 more
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
This is open-label, multicenter, Phase Ib study is designed to evaluate the Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in participants with advanced solid tumors.
- Trial name
- NCT05172856
- Testing
- IBI321
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Advanced Malignant Solid Tumors
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RCZY690 in Advanced Solid Tumors
This study aims to evaluate the safety and efficacy of RCZY690 therapy in participants with advanced malignant solid tumors. Participants will receive RCZY690 monotherapy until the end of the study.
- Trial name
- NCT07806175
- Testing
- RCZY690 Tablets, RCZY690 tables
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- Rongchang Pharmaceuticals Co., Ltd.
Advanced Solid Tumors or Lymphomas
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
CA-170 is a rationally designed and orally available, small molecule that directly targets the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell activation (VISTA) immune checkpoints and results…
- Trial name
- NCT02812875
- Testing
- CA-170
- Where
- 20 sites in United States, South Korea and 2 more
- Volunteers
- 71 people
- Sponsor
- Curis, Inc.
Advanced Solid Tumors
Study of the AL3810 in the Treatment of Advanced Solid Tumor
This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study
- Trial name
- NCT03117101
- Testing
- Lucitanib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Haihe Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.